ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Fibroblasts, Dermal"

  • Abstract Number: 1663 • ACR Convergence 2023

    Clinically Severe Systemic Sclerosis Skin Harbors Inflammatory Fibroblasts Associated with Lymphocytes and Plasmacytoid Dendritic Cells

    Kimberly Lakin1, Robert Spiera2, Yaxia Zhang1, David Oliver1, Aliza Bloostein1, Hiranmayi Ravichandran3, Niroshana Anandasabapathy3, Franck Barrat1, Jessica Gordon1 and Dana Orange4, 1Hospital for Special Surgery, New York, NY, 2Hosptial for Special Surgery, New York, NY, 3Weill Cornell Medical College, New York, NY, 4The Rockefeller University, New York, NY

    Background/Purpose: We have previously shown that skin fibroblast activation is related to clinical severity and resolves with improvement in diffuse systemic sclerosis (dcSSc). The immune…
  • Abstract Number: 0934 • ACR Convergence 2023

    Anti-fibrotic Effects of MT-5562, a Novel Potent Selective Autotaxin Inhibitor, in Preclinical Studies: Roles of Lysophosphatidic Acid in Autoimmune Diseases and Clues to Treat Skin and Lung Fibrosis in Systemic Sclerosis

    Hiroshi Matsuura1, Masahiro Kondo1, Ryoko Ohno1, Akina Ishii1, Mariam Piruzyan1, Kaori Funayama1, Yuuichi Ono1, Atsushi Iwamura1, Tadashi Endo1, Tomoya Akashi1, Taizo Tomari2, Noriko Uchiyama2, Noriyasu Seki1, Kenji Chiba1, Gabriela Kania3, Przemyslaw Blyszczuk4, Oliver Distler5, Tsutomu Takeuchi6 and Yuko Kaneko7, 1Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, 2Mitsubishi Tanabe Pharma Corporation, Fujisawa, Japan, 3University of Zurich, Zurich, Switzerland, 4Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 5Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 6Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 7Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Targeted small-molecule therapies to autotaxin (ATX), the lysophosphatidic acid (LPA)-producing enzyme, have been shown to be potentially effective in systemic sclerosis (SSc), but the…
  • Abstract Number: 1664 • ACR Convergence 2023

    Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis

    Minghua Wu1, Jerry Alonso2, Julio charles2, Brian Skaug2, Tingting Mills3, Maureen Mayes2 and Shervin Assassi4, 1Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, 2Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 3Biochemistry Department, University of Texas McGovern Medical School, Houston, TX, 4University of Texas McGovern Medical School at Houston, Houston, TX

    Background/Purpose: A prominent interferon (IFN) activation signature has been observed at the peripheral blood and end-organ levels in systemic sclerosis (SSc). However, the mechanisms by…
  • Abstract Number: 0936 • ACR Convergence 2023

    Impaired DNA Repair Responses Activate a Novel FOXO1-dependent Metabolic Remodelling in Patients with Progressive Systemic Sclerosis to Promote Fibrosis

    Lamia Khan, Desiree Redmond, Muhammad Elezzabi, Robert Gniadecki, Jan Willem Cohen Tervaert and Mohamed Osman, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Systemic sclerosis (SSc) is a deadly disease characterized by immune dysregulation, vasculopathy, and fibrosis. SSc is the most lethal rheumatic disease associated with the…
  • Abstract Number: 2367 • ACR Convergence 2023

    Characterization of the SFRP4+ PRG4+ Fibroblast Subpopulation in the Dermis of Healthy Skin and Its Relationship to SFRP4+ PRG4- Myofibroblasts in the Skin of Patients with Systemic Sclerosis

    Banafsheh Nazari1, Tracy Tabib2 and Robert Lafyatis2, 1University of Pittsburgh, Atlanta, GA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Systemic sclerosis (SSc) is a debilitating autoimmune disease characterized by extensive fibrosis affecting multiple organs. The fibrosis arises from the excessive production of collagen…
  • Abstract Number: 0941 • ACR Convergence 2023

    RUNX1 Expression and Binding Site Accessibility Is Associated with Increased Disease Severity in Systemic Sclerosis

    Rezvan Parvizi1, Zhiyun Gong1, Dillon Popovich1, Tamar Abel2, Helen Jarnagin1, Madeline Morrisson1, Tammara Wood2, Jonathan Garlick3, Monique Hinchcliff4, Patricia Pioli1 and Michael Whitfield1, 1Geisel School of Medicine at Dartmouth, Hanover, NH, 2Dartmouth College, Hanover, NH, 3Tufts University School of Dental Medicine, Boston, MA, 4Yale School of Medicine, Westport, CT

    Background/Purpose: Runt-related transcription factor 1 (RUNX1) is a member of the core-binding factor family that regulates proliferation, differentiation, and cell survival in multiple cell lineages.…
  • Abstract Number: 0942 • ACR Convergence 2023

    G Protein-coupled Receptor Kinase 5 in Fibrotic Tissue Remodeling

    Cuong Tran-Manh1, Thuong Trinh-Minh1, Christoph Liebel1, Chih-Wei Chen2 and Joerg Distler1, 1Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, 23 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany

    Background/Purpose: G-protein coupled receptor kinase 5, GRK5, is a central regulator of G protein-coupled receptors (GPCRs), a vast family of cell surface receptors involved in…
  • Abstract Number: 0943 • ACR Convergence 2023

    Attenuation of Fibroblast Activation and Fibrosis by Adropin in a Hedgehog-Dependent Manner

    Minrui Liang and Joerg Distler, Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany

    Background/Purpose: Adropin is a secretory protein encoded by the energy homeostasis - associated (ENHO) gene. Emerging evidence indicate its role in metabolism and energy homeostasis,…
  • Abstract Number: 0945 • ACR Convergence 2023

    The Nuclear Receptor TR4 Orchestrates Cytoskeletal Organization in a Gα12/ROCK-dependent Manner to Promote Myofibroblast Differentiation and Tissue Fibrosis in Systemic Sclerosis

    Yun Zhang1, Lichong Shen2, yi-nan Li1, Hermina Györfi1 and Joerg Distler1, 1Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, 2Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: Members of the superfamily of nuclear receptors have been implicated in inflammatory processes and pathologic tissue remodeling and have emerged as attractive targets for…
  • Abstract Number: 0946 • ACR Convergence 2023

    Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts

    Aurélien Chepy1, Marie Duhamel2, Solange Vivier1, Clément Chauvet1, Lucile Guilbert3, Eric Hachulla4, Sylvain Dubucquoi1, David Launay1, Michel Salzet2 and Vincent Sobanski1, 1Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, 2Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, 3CHU Lille, Institut d’Immunologie, Lille, France, 4CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France

    Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is unclear. Recently, we showed that immunoglobulins G…
  • Abstract Number: 0948 • ACR Convergence 2023

    Nintedanib Alters Fibroblast and Macrophage Diversity in a 3D Skin Model of Systemic Sclerosis (SSc)

    Noelle Kosarek1, Tamar Abel2, Sasha Shenk3, Tammara Wood2, Jonathan Garlick4, Patricia Pioli5 and Michael Whitfield5, 1Dartmouth Geisel School of Medicine, Lebanon, NH, 2Dartmouth College, Hanover, NH, 3Tufts University, Boston, MA, 4Tufts University School of Dental Medicine, Boston, MA, 5Geisel School of Medicine at Dartmouth, Hanover, NH

    Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs. While the tyrosine kinase inhibitor Nintedanib is…
  • Abstract Number: 0952 • ACR Convergence 2023

    Unraveling the Role of MiR-181 in Skin Fibrosis Pathogenesis by Targeting NUDT21

    Tingting Mills1, Minghua Wu2, Hydia Puente3, Jerry Alonso4, Julio charles4, Maureen Mayes4 and Shervin Assassi5, 1Biochemistry Department, University of Texas McGovern Medical School, Houston, TX, 2Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, 3UTHealth-Houston, Houston, TX, 4Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 5University of Texas McGovern Medical School at Houston, Houston, TX

    Background/Purpose: Nudix Hydrolase 21 (NUDT21, also known as CFIm25) is a master regulator of alternative polyadenylation. Previous studies have revealed that NUDT21 is significantly decreased…
  • Abstract Number: 0953 • ACR Convergence 2023

    Flavin-containing Monooxygenase (FMO3) Links the Gut and Fibrosis in Systemic Sclerosis

    Priyanka Verma1, Bharath Yalavarthi1, Karen Ho2, Lutfiyya Muhammad3, Seokjo Kim4, Johann Gudjonsson1, Rebecca C Schugar5, Mark Brown6, Xinmin Li6, Stanley L Hazen7, Swati Bhattacharyya1 and John Varga1, 1University of Michigan, Ann Arbor, MI, 2Northwestern University, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 44SCM Lifescience Co. Ltd, South Korea, Japan, 5Stanford University, Stanford, CA, 6Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 7Division of Endocrinology, Department of Medicine, Stanford University, Stanford, CA

    Background/Purpose: Trimethylamine (TMA) generated by the gut microbiome is converted into trimethylamine N-oxide (TMAO) via the host enzyme FMO3. The TMA-FMO3-TMAO metaorganismal axis has been…
  • Abstract Number: 0954 • ACR Convergence 2023

    Non-canonical WNTA Promotes Cytoskeletal Rearrangement and Integrin Alpha V Clustering via JNK and ROCK to Control the Activation of Latent TGFβ

    Thuong Trinh-Minh1, Chih-Wei Chen2, Cuong Tran Manh1, yi-nan Li1, Honglin Zhu3, Debomita Chakraborty4, Yun Zhang1, Simon Rauber5, Clara Dees5, Christina Bergmann6, Alexander Kreuter7, Christiane Reuter8, Florian Groeber-Becker8, Beate Eckes9, Oliver Distler10, Andreas Ramming11, Georg Schett12 and Joerg Distler1, 1Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, 23 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 33 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. 5 Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China, 43 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 53 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 6Department Internal Medicine, University Hospital Erlangen, Germany, Erlangen, Germany, 7Clinic for Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Clinic, Oberhausen, Germany, 8Translational Center for Regenerative Therapies, Fraunhofer Institute for Silicate Research (ISC) Würzburg, Würzburg, Germany, 9Translational Matrix Biology, University of Cologne, Cologne, Germany. 9 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Köln, Germany, 10Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 11Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 12Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder with vasculopathy, inflammation, and fibrosis of the skin and organs. Fibrosis is caused by the abnormal…
  • Abstract Number: 007 • 2023 Pediatric Rheumatology Symposium

    Single Cell RNA Sequencing Analysis of the Skin to Evaluate the Effect of Autologous Stem Cell Transplant on Fibroblast Populations in Juvenile Onset Systemic Sclerosis

    Claire Cheng, Giffin Werner, Anwesha Sanyal and Kathryn Torok, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Juvenile systemic sclerosis (JSSc) is a rare autoimmune disease associated with high morbidity. Inflammatory driven multi-organ fibrosis is similar to adult-onset SSc, with 40%…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology